\
&
Contact us
\
&
Contact us
Published on | 2 years ago
Programmes AI Continent Deployment: Best use of technologiesThe European Commission has opened a call for tender for the Procurement of the Technical Specifications for the Local Digital Twins (LDTs) Toolbox.
The aim of this procurement is to define the technical specifications of this Local Digital Twin (LDT) Toolbox. Economic operators interested in this call are invited to submit a tender via the electronic submission system (e-Submission) available from the TED e-Tendering website.
In order to propose the technical specifications of the LDT toolbox to be later developed and deployed (see DIGITAL workprogramme 2021-2022, section 2.2.1.2.3), this procurement needs to:
The reason for purchasing this work is to make the best possible set of tools and their technical specs for the toolbox procurement, prepared by a relevant consortium, given that this expertise is not easily available in house.
Economic operators interested in this call are invited to submit a tender via the electronic submission system (e-Submission) available from the TED e-Tendering website:
Tenders are to be submitted via the electronic submission system on the TED e-tendering website
Deadline for submissions: 27/12/2022 (16h00 CET)
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
